ES2588010T3 - Polipéptidos de Yersinia spp. y métodos de uso - Google Patents

Polipéptidos de Yersinia spp. y métodos de uso Download PDF

Info

Publication number
ES2588010T3
ES2588010T3 ES06719369.8T ES06719369T ES2588010T3 ES 2588010 T3 ES2588010 T3 ES 2588010T3 ES 06719369 T ES06719369 T ES 06719369T ES 2588010 T3 ES2588010 T3 ES 2588010T3
Authority
ES
Spain
Prior art keywords
seq
kda
polypeptides
polypeptide
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06719369.8T
Other languages
English (en)
Spanish (es)
Inventor
Daryll A. Emery
Darren E. Straub
Laura Wonderling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitopix LLC
Original Assignee
Epitopix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix LLC filed Critical Epitopix LLC
Application granted granted Critical
Publication of ES2588010T3 publication Critical patent/ES2588010T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES06719369.8T 2005-01-21 2006-01-20 Polipéptidos de Yersinia spp. y métodos de uso Expired - Lifetime ES2588010T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64610605P 2005-01-21 2005-01-21
US646106P 2005-01-21
PCT/US2006/002474 WO2006079076A2 (en) 2005-01-21 2006-01-20 Yersinia spp. polypeptides and methods of use

Publications (1)

Publication Number Publication Date
ES2588010T3 true ES2588010T3 (es) 2016-10-28

Family

ID=36649588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06719369.8T Expired - Lifetime ES2588010T3 (es) 2005-01-21 2006-01-20 Polipéptidos de Yersinia spp. y métodos de uso

Country Status (12)

Country Link
US (8) US8563004B2 (enExample)
EP (3) EP2431382A1 (enExample)
JP (3) JP2008528512A (enExample)
CN (1) CN101142230A (enExample)
AU (1) AU2006206234B2 (enExample)
BR (1) BRPI0606506A2 (enExample)
CA (1) CA2595163A1 (enExample)
DK (1) DK1848732T3 (enExample)
ES (1) ES2588010T3 (enExample)
MX (1) MX2007008723A (enExample)
NZ (1) NZ556651A (enExample)
WO (1) WO2006079076A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279511T3 (es) * 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
DK1353689T3 (da) * 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
CA2595163A1 (en) 2005-01-21 2006-07-27 Epitopix, Llc Yersinia peptides grown in media comprising 2,2'-dipyridyl, compositions and kits thereof
KR102211724B1 (ko) 2011-05-31 2021-02-03 허치슨 바이오필름 메디컬 솔루션스 리미티드 세포 응집물의 분산 및 분리
US9631221B1 (en) * 2011-09-02 2017-04-25 Becton, Dickinson And Company Identification of microorganisms using MALDI-TOF-MS on-plate extraction
WO2013099806A1 (ja) 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
US9701760B2 (en) * 2012-02-13 2017-07-11 National University Corporation Kyoto Institute Of Technology Peptide having affinity for silicon nitride (Si3N4), and use therefor
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US9017953B2 (en) * 2012-05-18 2015-04-28 Washington University Biomarker and therapeutic for urinary tract infection
RU2549712C1 (ru) * 2013-11-26 2015-04-27 Федеральное казенное учреждение здравоохранения "Ростовский-на-Дону ордена Трудового Красного Знамени научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека CПОСОБ ВЫДЕЛЕНИЯ ИНГИБИТОРА СЕКРЕЦИИ СИДЕРОФОРОВ, СИНТЕЗИРУЕМОГО pgm- ШТАММАМИ Y. pestis И ВЫДЕЛЕННЫЙ ИНГИБИТОР
FR3024903A1 (fr) 2014-08-14 2016-02-19 Biomerieux Sa Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse
WO2016058007A2 (en) * 2014-10-10 2016-04-14 Rare Element Resources, Ltd. Processing for the extraction of rare earth elements
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
EP3373964A1 (en) 2015-11-09 2018-09-19 Epitopix, LLC Polypeptides of fusobacterium and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
MX2019009409A (es) 2017-02-10 2019-09-27 Epitopix Llc Proteinas y composiciones de inmunizacion que contienen proteinas de pasteurella y metodos de uso.
AU2020367821A1 (en) * 2019-10-18 2022-05-12 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN113679829B (zh) * 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
ES2279511T3 (es) * 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
US5830479A (en) 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
AU1860095A (en) 1994-03-22 1995-10-09 Pfizer Inc. (pasteurellaceae) antigens and related vaccines
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
WO1998024912A2 (en) * 1996-12-04 1998-06-11 Heska Corporation Recombinant plague vaccine
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
DK1353689T3 (da) 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0127657D0 (en) * 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
EP1784417B1 (en) 2004-08-25 2016-05-18 Epitopix, LLC Fusobacterium polypeptides and methods of use
CA2595163A1 (en) 2005-01-21 2006-07-27 Epitopix, Llc Yersinia peptides grown in media comprising 2,2'-dipyridyl, compositions and kits thereof
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006113907A2 (en) * 2005-04-20 2006-10-26 The General Hospital Corporation Escherichia coli o157:h7 proteins and uses thereof

Also Published As

Publication number Publication date
US20110206674A1 (en) 2011-08-25
AU2006206234B2 (en) 2012-01-12
DK1848732T3 (en) 2016-11-14
US20140170164A1 (en) 2014-06-19
EP2361926A3 (en) 2011-12-21
CN101142230A (zh) 2008-03-12
US9352029B2 (en) 2016-05-31
BRPI0606506A2 (pt) 2009-06-30
US20160228527A1 (en) 2016-08-11
US9109018B2 (en) 2015-08-18
EP2361926A2 (en) 2011-08-31
EP1848732B1 (en) 2016-07-27
AU2006206234A1 (en) 2006-07-27
US9085613B2 (en) 2015-07-21
JP2008528512A (ja) 2008-07-31
WO2006079076A3 (en) 2007-03-29
JP6224655B2 (ja) 2017-11-01
US20060269564A1 (en) 2006-11-30
JP2013018779A (ja) 2013-01-31
MX2007008723A (es) 2007-09-12
US20160051655A1 (en) 2016-02-25
US20140161834A1 (en) 2014-06-12
US9221899B2 (en) 2015-12-29
US20150307598A1 (en) 2015-10-29
JP2015193645A (ja) 2015-11-05
US9801932B2 (en) 2017-10-31
CA2595163A1 (en) 2006-07-27
NZ556651A (en) 2010-05-28
US20140161838A1 (en) 2014-06-12
US8563004B2 (en) 2013-10-22
JP6178059B2 (ja) 2017-08-09
US9085612B2 (en) 2015-07-21
WO2006079076A2 (en) 2006-07-27
EP1848732A2 (en) 2007-10-31
EP2431382A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
Walton The cyclic peptide toxins of amanitaand other poisonous mushrooms
Lagoutte et al. Simultaneous surface display and cargo loading of encapsulin nanocompartments and their use for rational vaccine design
Conlon et al. Isolation of peptides of the brevinin‐1 family with potent candidacidal activity from the skin secretions of the frog Rana boylii
Vialás et al. Cell surface shaving of C andida albicans biofilms, hyphae, and yeast form cells
Prax et al. Glucose augments killing efficiency of daptomycin challenged Staphylococcus aureus persisters
Wasinpiyamongkol et al. Blood‐feeding and immunogenic Aedes aegypti saliva proteins
FR2794865A1 (fr) Methode de detection precoce des flavivirus et ses applications
Wang et al. A novel protein isolated from the serum of rabbitfish (Siganus oramin) is lethal to Cryptocaryon irritans
Morgan et al. A proteomic analysis of Sarcoptes scabiei (Acari: Sarcoptidae)
Piras et al. Identification of immunoreactive proteins of Mycobacterium avium subsp. paratuberculosis
Hernychova et al. Detection and identification of Coxiella burnetii based on the mass spectrometric analyses of the extracted proteins
Tan et al. Involvement of Urm1, a ubiquitin-like protein, in the regulation of oxidative stress response of toxoplasma gondii
Wüllner et al. Interspecies comparison of the bacterial response to allicin reveals species‐specific defense strategies
Hernández-González et al. Proteomic analysis of in vitro newly excysted juveniles from Fasciola hepatica
Di Maggio et al. Comparative proteomics of adult Paragonimus kellicotti excretion/secretion products released in vitro or present in the lung cyst nodule
Biswas et al. Infection with Campylobacter jejuni Induces Tyrosine‐Phosphorylated Proteins into INT‐407 Cells
Chen et al. Haemocyte protein expression profiling of scallop Chlamys farreri response to acute viral necrosis virus (AVNV) infection
Aivaliotis et al. Membrane proteome analysis of the green‐sulfur bacterium Chlorobium tepidum
Haines et al. The major protein in the midgut of teneral Glossina morsitans morsitans is a molecular chaperone from the endosymbiotic bacterium Wigglesworthia glossinidia
Senneby et al. Identification of two abundant Aerococcus urinae cell wall-anchored proteins
Cheng et al. Vibrio parahaemolyticus associated with mass mortality of postlarval abalone, Haliotis diversicolor supertexta (L.), in Sanya, China
US20240009301A1 (en) Immunogenic compositions for producing neutralising antibodies against sars-cov
Krajaejun et al. The 74-Kilodalton immunodominant antigen of the pathogenic oomycete Pythium insidiosum is a putative Exo-1, 3-ß-Glucanase
FR2794864A1 (fr) Methode de detection precoce des flavivirus et ses applications
Tabatabai Identification of Pasteurella multocida CHAPS-soluble outer membrane proteins